The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

As you can see below, at the end of June 2024, Pfizer had US$69.9b of debt, up from US$65.7b a year ago. Click the image for ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

We recently published a list of 10 Best Innovative Stocks that Pay Dividends. In this article, we are going to take a look at ...

A new COVID variant is raising questions and capturing the attention of researchers heading into the fall and winter season.

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer PFE in the ...

Low consumer demand scuppered a previous vaccine in the 1990s, but the situation is very different now. Cases of Lyme have ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.